{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:01:01Z","timestamp":1788415261641,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clgc.2024.102181","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T02:23:42Z","timestamp":1722392622000},"page":"102181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0184-3467","authenticated-orcid":false,"given":"Moshe C.","family":"Ornstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4853-1401","authenticated-orcid":false,"given":"Laeth","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0960-7269","authenticated-orcid":false,"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Marcela","family":"Diaz-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pat","family":"Rayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Beckermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5181-490X","authenticated-orcid":false,"given":"Amanda","family":"Nizam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0168-2069","authenticated-orcid":false,"given":"Christopher E.","family":"Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Gilligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-080X","authenticated-orcid":false,"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.clgc.2024.102181_bib0001","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clgc.2024.102181_bib0002","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clgc.2024.102181_bib0003","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clgc.2024.102181_bib0004","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clgc.2024.102181_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003473","article-title":"Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"9","author":"Tzeng","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"24","key":"10.1016\/j.clgc.2024.102181_bib0006","doi-asserted-by":"crossref","first-page":"6687","DOI":"10.1158\/1078-0432.CCR-21-2283","article-title":"Treatment-free survival after immune checkpoint inhibitor therapy versus targeted therapy for advanced renal cell carcinoma: 42-month results of the CheckMate 214 trial","volume":"27","author":"Regan","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.clgc.2024.102181_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003743","article-title":"Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067","volume":"9","author":"Regan","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2024.102181_bib0008","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/CMR.0000000000000793","article-title":"Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors","volume":"32","author":"Mantia","year":"2022","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.clgc.2024.102181_bib0009","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s40425-019-0615-z","article-title":"A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy","volume":"7","author":"Ornstein","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2024.102181_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001901","article-title":"Considerations for treatment duration in responders to immune checkpoint inhibitors","volume":"9","author":"Marron","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2024.102181_bib0011","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS366","article-title":"PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)","volume":"39","author":"Zhang","year":"2021","journal-title":"JCO"},{"issue":"7","key":"10.1016\/j.clgc.2024.102181_bib0012","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/cam4.4587","article-title":"Salvage nivolumab and ipilimumab after prior anti-PD-1\/PD-L1 therapy in metastatic renal cell carcinoma: a meta-analysis","volume":"11","author":"Yang","year":"2022","journal-title":"Cancer Med"},{"issue":"25","key":"10.1016\/j.clgc.2024.102181_bib0013","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1200\/JCO.21.02938","article-title":"Phase II study of nivolumab and salvage nivolumab\/ipilimumab in treatment-naive patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)","volume":"40","author":"Atkins","year":"2022","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.clgc.2024.102181_bib0014","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1200\/JCO.20.02295","article-title":"Optimized management of nivolumab and ipilimumab in advanced renal cell carcinoma: a response-based Phase II study (OMNIVORE)","volume":"38","author":"McKay","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clgc.2024.102181_bib0015","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4576","article-title":"Efficacy of nivolumab\/ipilimumab in patients with initial or late progression with nivolumab: Updated analysis of a tailored approach in advanced renal cell carcinoma (TITAN-RCC)","volume":"39","author":"Grimm","year":"2021","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.clgc.2024.102181_bib0016","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/sim.4780140404","article-title":"Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes","volume":"14","author":"Thall","year":"1995","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.clgc.2024.102181_bib0017","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/OP.21.00419","article-title":"Clinical review on the management of metastatic renal cell carcinoma","volume":"18","author":"Tran","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"suppl_8","key":"10.1016\/j.clgc.2024.102181_bib0018","article-title":"Treatment-free survival following discontinuation of first-line nivolumab plus ipilimumab or sunitinib in patients with advanced renal cell carcinoma: CheckMate 214 analysis","volume":"29","author":"McDermott","year":"2018","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.clgc.2024.102181_bib0019","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2014.58.1041","article-title":"Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab","volume":"33","author":"McDermott","year":"2015","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clgc.2024.102181_bib0020","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clgc.2024.102181_bib0021","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1200\/JCO.2016.71.1184","article-title":"A phase II study of intermittent sunitinib in previously untreated patients with metastatic renal cell carcinoma","volume":"35","author":"Ornstein","year":"2017","journal-title":"J Clin Oncol"},{"issue":"0","key":"10.1016\/j.clgc.2024.102181_bib0022","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(22)00793-8","article-title":"Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2\/3 trial","volume":"0","author":"Brown","year":"2023","journal-title":"Lancet Oncol"},{"issue":"suppl_2","key":"10.1016\/j.clgc.2024.102181_bib0023","article-title":"Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study","volume":"34","author":"Iacovelli","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2024.102181_bib0024","doi-asserted-by":"crossref","first-page":"01","DOI":"10.3389\/fonc.2022.960751","article-title":"Nivolumab drug holiday in patients treated for metastatic renal cell carcinoma: a real-world, single-centre experience","volume":"12","author":"Bimbatti","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2024.102181_bib0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2018.12.006","article-title":"The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: a phase 2 clinical trial","volume":"108","author":"Bjarnason","year":"2019","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.clgc.2024.102181_bib0026","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/annonc\/mdv030","article-title":"Alternate sunitinib schedules in patients with metastatic renal cell carcinoma","volume":"26","author":"Kalra","year":"2015","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2024.102181_bib0027","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(19)30513-3","article-title":"Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study","volume":"20","author":"Ornstein","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102181_bib0028","unstructured":"ClinicalTrials.Gov. Trying to find the correct length of treatment with immune checkpoint therapy - Full text view - ClinicalTrials.gov. Accessed July 3, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04637594"},{"issue":"33","key":"10.1016\/j.clgc.2024.102181_bib0029","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1200\/JCO.20.00131","article-title":"Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153","volume":"38","author":"Waterhouse","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2024.102181_bib0030","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamaoncol.2023.1891","article-title":"Association between duration of immunotherapy and overall survival in advanced non\u2013small cell lung cancer","volume":"9","author":"Sun","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102181_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-related adverse events and survival among patients with metastatic nsclc treated with immune checkpoint inhibitors","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.clgc.2024.102181_bib0032","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2024.102181_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001622","article-title":"Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade \u22652 immune-related adverse events in patients with cancer","volume":"8","author":"Allouchery","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T16:42:49Z","timestamp":1746463369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324001526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1558767324001526"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102181","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102181"}}